Latest Updates on Monoclonal Antibodies

Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. JOHN WHYTE: Welcome, everyone. I’m Dr. John Whyte, Chief Medical Officer at WebMD, and you’re watching Coronavirus in Context, where we try to break down what’s happening with coronavirus and how it impacts your life. We’ve been talking a […]

Read More

INO-4800 DNA Vaccine Induces Neutralizing Antibodies and T cell Activity Against Global SARS-CoV-2 Variants

Abstract Global surveillance has identified emerging SARS-CoV-2 variants of concern (VOC) associated with broadened host specificity, pathogenicity, and immune evasion to vaccine induced immunity. Here we compared humoral and cellular responses against SARS-CoV-2 VOC in subjects immunized with the DNA vaccine, INO-4800. INO-4800 vaccination induced neutralizing antibodies against all variants […]

Read More

Neutralizing the Virus: A Focus on SARS-CoV-2–Specific Monoclonal Antibodies

Educational Impact Challenge The goal of this activity is to increase clinicians’ knowledge and understanding of how neutralizing monoclonal antibodies function to both treat patients with COVID-19 and prevent disease in others.  Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after […]

Read More

Covid-19: Eight in 10 Wuhan residents with antibodies had no symptoms, finds study

More than three quarters of Wuhan residents who tested positive for SARS-CoV-2 antibodies had experienced no covid-19 symptoms and just under half developed long lasting neutralising antibodies, show results from the first long term seroprevalence study from the epicentre of the outbreak in China.1 Researchers tested 9542 people from 3556 […]

Read More

Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study

First long-term Wuhan seroprevalence study finds 6.9% of population had antibodies against COVID-19 by April 2020—with 82% of cases asymptomatic. 40% developed neutralising antibodies lasting at least 9 months. Read   Créditos: Comité científico Covid

Read More